3515c93d-73e5-4aec-9186-2e8bd47deae2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 85.0869267624914
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- WNT_BETA_CATENIN_SIGNALING+0.290
- UNFOLDED_PROTEIN_RESPONSE+0.230
- G2M_CHECKPOINT+0.190
- PROTEIN_SECRETION+0.190
- ANGIOGENESIS+0.180
- HEDGEHOG_SIGNALING+0.150
- MITOTIC_SPINDLE+0.120
- UV_RESPONSE_DN+0.120
- MYC_TARGETS_V1+0.110
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.390
- ALLOGRAFT_REJECTION-0.360
- INTERFERON_GAMMA_RESPONSE-0.350
- OXIDATIVE_PHOSPHORYLATION-0.350
- PANCREAS_BETA_CELLS-0.330
- INTERFERON_ALPHA_RESPONSE-0.290
- TNFA_SIGNALING_VIA_NFKB-0.290
- IL6_JAK_STAT3_SIGNALING-0.280
- INFLAMMATORY_RESPONSE-0.270
- COMPLEMENT-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932838 | — | — | 0.811 |
| 2 | TCGA-D8-A1XD-01A-11R-A14D-07 | — | B | 0.799 |
| 3 | 20100144.Her2HRpos | — | D | 0.799 |
| 4 | C3N-02435 | — | cohortSQ1 | 0.794 |
| 5 | TCGA-NC-A5HP-01A-11R-A26W-07 | — | cohortSQ1 | 0.783 |
| 6 | TCGA-CN-5356-01A-01R-1436-07 | — | — | 0.769 |
| 7 | SRR5903551 | — | cohortA1 | 0.769 |
| 8 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.767 |
| 9 | MNG335 | — | — | 0.766 |
| 10 | a9e8922f-fd6c-412d-85f5-40f5ea9b5455 | — | — | 0.762 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.040 | Idelalisib | — uncovered |